{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-010481","form_type":"8-K","ticker":"ARTV","cik":"0001817241","company_name":"Artiva Biotherapeutics, Inc.","filed_at":"2025-01-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.031836+00:00","generated_at":"2026-05-27T07:14:07.048257+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"high","headline":"Artiva appoints Daniel Baker to board; forms Clinical Strategy Committee","bullets":["Daniel Baker, Ph.D. appointed as Class I director effective Jan 28, 2025; term expires at 2025 annual meeting.","Baker also named to Clinical Strategy Committee; Laura Bessen, Brian Daniels, Laural Stoppel appointed as members; Diego Miralles as chair.","Baker receives $40K annual board retainer and initial option for 27,500 shares; one-third vested immediately, remainder over two years.","Clinical Strategy Committee members get $7,500 annual retainer; chair receives $15,000."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-010481","json":"https://secwatch.observer/filing/0000950170-25-010481.json","markdown":"https://secwatch.observer/filing/0000950170-25-010481.md","text":"https://secwatch.observer/filing/0000950170-25-010481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/0000950170-25-010481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/artv-20250128.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T07:14:07.048257+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c64c8873cf","claim":"Daniel Baker was appointed as Class I Director at Artiva Biotherapeutics, Inc..","evidence_excerpt":"On January 28, 2025, the Board of Directors (the “Board”) of Artiva Biotherapeutics, Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Daniel Baker, Ph.D. as (i) a Class I director of the Company, with a term of office expiring at the 2025 annual meeting of stockholders","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1817241/000095017025010481/0000950170-25-010481-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}